Artes Medical - Worst Pharma Stocks of 2007

Company: Artes Medical
Starting stock price: $8.33
Ending stock price: $2.27
Percent Change: -72.75%

Details: Artes Medical develops and markets injectable products for cosmetic use by dermatologists and plastic surgeons. Its first product, ArteFill, won FDA approval in October 2006 and started shipping in 2007. It competes with collagen injections and Botox.

Artes Medical - Worst Pharma Stocks of 2007

Suggested Articles

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.

House Democrats passed Pelosi's drug pricing bill, named after the late Rep. Elijah Cummings, in a mostly party-line vote Thursday.